Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Particle Therapy
... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens Therapy, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Alpha Emitters
... CAGR of 20.9% over the analysis period 2024-2030. Bone Metastasis Application, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$993.8 Million by the end of the ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary Test, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of ... Read More
-
Intraoperative Radiation Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Systems / Accelerators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$22.9 Million by the end ... Read More
-
Antineoplastic Agents
... CAGR of 7.3% over the analysis period 2024-2030. Chemotherapeutic Agents Application, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$137.9 Billion by the end of the ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
-
Next Generation Cancer Diagnostics
... 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing Technology, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion ... Read More
-
Hematological Malignancies
... CAGR of 6.2% over the analysis period 2024-2030. Leukemia Disease, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of the analysis ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas Therapeutics & Diagnostics, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and ... Read More
-
Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 202
... the past decade. Progress in minimally invasive techniques and an increase in cancer prevalence rates have contributed significantly to this boom. Initially, the market for interventional oncology was underdeveloped owing to the long-standing use of ... Read More
-
Ewing Sarcoma - Global Clinical Trials Review, 2025
... data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials ... Read More
-
Global Ovarian Cancer Drugs Market - 2024-2032
... during the forecast period 2024-2031. Ovarian cancer is the growth of abnormal cancerous cells in the ovaries, fallopian tube, or peritoneum- the major parts of the woman’s reproductive system. Ovaries are made up of different ... Read More
-
Organs-on-Chips Market by Type of Product (organ based and disease based), Type of Organ (single organ based and multi organ based), Type of Single Organ based Model (liver, lung, brain, heart, intestine, kidney and other organs), Type of Material of Construction (polydimethylsiloxane, other polymer, glass and others), Purpose (research and therapeutic), Application Area (drug discovery / toxicity testing, cancer research, stem cell research, tissue engineering / regenerative medicine and others), End User (pharmaceutical and biotech companies, academic and research players, cosmetic industry players and other end users), Key Geographical Regions and Leading Players: Industry Trends and Global Forecasts, Till 2035
... of 25. 6% during the forecast period, till 2035. The opportunity for organ on a chip market has been distributed across the following segments: Type of Product Organ based Disease based Type of Organ Single ... Read More
Research Assistance
